NCT05079360: Efficacy Evaluation of Sabizabulin Monotherapy Versus Active Control for Treatment of ER+HER2- Metastatic Breast Cancer

Breast Cancer Type: HR+ & HER2-negative
Hormone Mutations: ER+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Not yet recruiting
Phase 2
Drug Category: Serine-Threonine Kinase Inhibitor, Endocrine (Hormone Therapy, Chemotherapy

Key Eligibility Criteria:

Gender: All
Age: 18 Years to 100 Years (Adult, Older Adult)
Location of Metastases: 
Additional Notes: 
Exclusions: Patients with unstable symptomatic central nervous system metastases – see trial for details; Patients who have not received a non-steroidal aromatase inhibitor (AI) (e.g. Arimidex/anastrozole, Aromasin/exemestane, Femara/letrozole) or SERD (e.g. Faslodex/fulvestrant, Zoladex, Lupron) in combination with a CDK 4/6 inhibitor (e.g. Ibrance/palbociclib, Verzenio/abemaciclib, Kisqali/ribociclib) for adjuvant or metastatic breast cancer (MBC)

Comments are closed.

Up ↑